Development of new c-Met inhibitors and application of corresponding multitarget tyrosine kinase inhibitors in tumor therapy

With the continuous progress of the times, lung cancer has gradually emerged in people's lives, which has a significant impact on human health. Tumor targeting is mainly used to treat specific abnormal targets in human tumor cells or tissues, and eliminate tumor cell-specific lesions by blocking signal and metabolic pathways. In this article, we developed a new type of c-Met inhibitor, and analyzed its application in tumor therapy together with a multitarget tyrosine kinase inhibitor. In this experiment, six compounds were screened, one of which was used as a positive control to evaluate the kinase inhibitory activity of candidate compounds. In this test, the dilution concentration grade, dilution gradient grade and porosity are taken as the dependent variables of each compound, and different results are obtained by adjusting each factor. The detection of c-Met kinase activity showed that c-Met inhibitors showed good kinase inhibitory activity. The results of inhibitory activity test showed that SIPI6931 compound on EGFR, KDR, c-Met kinase showed weak inhibitory activity, and had strong tolerance to SNU-5 cells combined with SIPI6931 compound cell activity. In this paper, the combination of new c-Met inhibitors and multitarget tyrosine kinase inhibitors has greatly promoted the development of tumor therapy.

Automated summary

With the progress of times, lung cancer has become increasingly prevalent and has a significant impact on human health. Tumor targeting involves targeting specific abnormal targets in tumor cells or tissues to eliminate tumor cell-specific lesions. This study developed a new c-Met inhibitor and analyzed its application in tumor therapy in combination with a multitarget tyrosine kinase inhibitor. The results showed that the combination of these inhibitors greatly promoted the development of tumor therapy.